NR

Norbert Riedel

Industry Advisor at Agent Capital

Norbert Riedel, Ph.D., is president and chief executive officer of Aptinyx Inc., a biopharmaceutical company, where he also serves as a member of the board of directors. Dr. Riedel was formerly president and chief executive officer of Naurex Inc., the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, he served in various roles at Baxter International Inc., most recently as corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst-Marion Roussel (now Sanofi).


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Agent Capital

Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Their investment areas of focus are new products and technologies for oncology, immunology, neurology and rare disease indications. They make direct equity investments across all stages of development and types of financing rounds.


Industries

Employees

11-50

Links